In patients with T2DM and symptomatic coronary artery disease, the addition of vildagliptin to ongoing metformin showed better glycemic control, lower inflammatory markers (IL-1β and C reactive protein), higher protective markers (adiponectin and HDL-C), and improved lipid profile compared to glimepiride/metformin therapy [151]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.